Picture of Stayble Therapeutics AB logo

STABL — Stayble Therapeutics AB Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Annual cashflow statement for Stayble Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

C2020
December 31st
2021
December 31st
R2022
December 31st
2023
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Interim ReportARSInterim ReportARSPRESS
Standards:
SAS
SAS
SAS
SAS
SAS
Status:FinalFinalFinalFinalPreliminary
Net Income/Starting Line-15.5-12.1-24.5-23.7-6.93
Non-Cash Items—-0.078—0.193—
Other Non-Cash Items
Changes in Working Capital-8.662.54-0.0950.0070.208
Change in Accounts Receivable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-24.1-9.63-24.6-23.5-6.72
Capital Expenditures—-0.001—0—
Purchase of Fixed Assets
Other Investing Cash Flow Items——0.001——
Sale of Fixed Assets
Cash from Investing Activities—-0.0010.0010—
Financing Cash Flow Items-3.81-5.190-6.85-0.213
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities31.236.20256.98
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash7.0426.6-24.61.230.257